In a recent study, 31 patients with previously negative prostate biopsy, but persistently elevated serum PSA, were imaged with 68Ga-labeled PSMA PET/CT and then underwent both standard systematic biopsy and PET/CT-US fusion targeted biopsy (9): Among the 13 patients who were negative on PSMA PET imaging, none were diagnosed with clinically significant cancer; in the 18 patients positive by PSMA PET imaging, PET/CT-US fusion targeted biopsy detected all 12 patients with clinically significant cancer while standard systematic biopsy detected only 10 patients. The gene discussed is FOLH1; the disease is cancer.